About Our Team

Mercy's Founding Pair

The Mercy Story

The kernel of Mercy BioAnalytics was sown when Paul Blavin, financier and philanthropist, met a brilliant freshman enrolled in the Blavin Scholars Program at the University of Michigan. That young man was Joseph Sedlak.

With Paul’s support, Joseph graduated summa cum laude from the University of Michigan with a degree in biomedical engineering, entered Harvard Medical School, and along the way became Paul’s adopted son. Through his studies at labs across Harvard and MIT, Joseph’s interest was piqued when he recognized the largest unmet need in oncology was the early detection of cancer.

As a young scientist comfortable with new concepts, such as nanotechnology and single cell analysis, Joseph developed the novel idea on which he founded Mercy BioAnalytics with Paul in 2018: using single extracellular vesicles for early cancer detection. The company leverages Paul’s business savvy and connections with Joseph’s scientific curiosity in its mission to improve the lives of patients suffering from cancer.

Paul and Joseph have gathered around them a stellar group of advisors and colleagues with decades of experience and success in cancer detection and diagnostics who share their mission.

Experienced Team
Founding Pair

The Mercy Story

The kernel of Mercy BioAnalytics was sown when Paul Blavin, financier and philanthropist, met a brilliant freshman enrolled in the Blavin Scholars Program at the University of Michigan. That young man was Joseph Sedlak.

With Paul’s support, Joseph graduated summa cum laude from the University of Michigan with a degree in biomedical engineering, entered Harvard Medical School, and along the way became Paul’s adopted son. Through his studies at labs across Harvard and MIT, Joseph’s interest was piqued when he recognized the largest unmet need in oncology was the early detection of cancer.

Experienced Team

As a young scientist comfortable with new concepts, such as nanotechnology and single cell analysis, Joseph developed the novel idea on which he founded Mercy BioAnalytics with Paul in 2018: using single extracellular vesicles for early cancer detection. The company leverages Paul’s business savvy and connections with Joseph’s scientific curiosity in its mission to improve the lives of patients suffering from cancer.

Paul and Joseph have gathered around them a stellar group of advisors and colleagues with decades of experience and success in cancer detection and diagnostics who share their mission.

Team Mercy

Paul Blavin

Paul Blavin

Co-Founder, Chief Executive Officer

Dawn Mattoon, PhD

Dawn Mattoon, PhD

Chief Operating Officer

Eric Huang, PhD

Eric Huang, PhD

Chief Scientific Officer

Diane Marcou

Diane Marcou

Chief Financial Officer

Vera Imper, PhD

Vera Imper, PhD

Senior Advisor, Corporate Development

Emily Winn-Deen, PhD

Emily Winn-Deen, PhD

Sr. Vice President of Diagnostics Strategy

Board of Directors

Stanley Lapidus

Stanley Lapidus

Chairman

Paul Meister

Paul Meister

Sonja Hoel Perkins

Sonja Hoel Perkins

Paul Blavin

Paul Blavin

Joseph Sedlak

Joseph Sedlak

Scientific Founder, Advisor

Advisors

Alberto Gutierrez, PhD

Alberto Gutierrez, PhD

Christine Berg, MD

Christine Berg, MD

David Ransohoff, MD

David Ransohoff, MD

Randy Schekman, PhD

Randy Schekman, PhD

Steven Skates, PhD

Steven Skates, PhD

“Never doubt that a small group of thoughtful, committed citizens can change the world; indeed, it’s the only thing that ever has.”

– Margaret Mead

Unparalleled Innovation.

Real collaboration.

Join Mercy BioAnalytics on our lifesaving mission to detect cancer early when it is most curable

ACCELERATING UNDERSTANDING

For pharmaceutical companies, Mercy Halo offers an opportunity to accelerate clinical development programs through exploratory sample analysis for key tumor-derived biomarkers. Future offerings will include patient screening for clinical trial enrollment and companion diagnostic development to support new drug commercialization.

Mercy BioAnalytics works for companies who want to increase the chances of a drug’s success in clinical trials. Mercy Halo helps identify patients whose cancer has the right molecular profile for their clinical program, monitor their response to investigational drugs or combinations of drugs, and perform retrospective analyses on previously archived plasma or serum samples.